IGHE and neoplasm: In patients whose serum IgE levels could be evaluated before and after treatment with omalizumab (n = 13), 11 patients had an increase in serum IgE levels as the skin rash improved (mean 437/μL rising to 730/μL, p = 0.014) (Figure 1B).